Literature DB >> 9723829

Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

C M da Silva1, F L David, M N Muscará, S S Sousa, J G Ferraz, G de Nucci, N C Polimeno, J Pedrazzoli.   

Abstract

AIMS: To evaluate plasma hydroxy-metronidazole/metronidazole ratio as a dynamic liver function test in HCV-infected individuals with/without liver disease, in the absence of liver cirrhosis.
METHODS: Metronidazole was administered intravenously in healthy volunteers, asymptomatic anti-HCV-positive blood donors, and in chronic hepatitis C patients. Serology to HCV was determined by a second generation assay and confirmed by gelatin particle agglutination test using recombinant antigens C22-3 and C200. Plasma concentration of metronidazole and hydroxy-metronidazole was measured by high performance liquid chromatography in samples collected 5, 10, 20 and 30 min following the end of metronidazole infusion.
RESULTS: Chronic hepatitis C patients had abnormal liver enzymes, while healthy volunteers and anti-HCV-positive blood donors had normal liver biochemistry tests. Plasma metronidazole concentration was similar in all groups studied. Plasma hydroxy-metronidazole/metronidazole ratio was significantly reduced in HCV-infected subjects, an effect observed 10 min after the end of drug infusion.
CONCLUSIONS: Metronidazole clearance is impaired in anti-HCV-positive blood donors and chronic hepatitis C patients, indicating that HCV is capable of affecting liver function at early stages of the disease. The metronidazole clearance test can detect impaired liver function in HCV-infected individuals even in the absence of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723829      PMCID: PMC1873660          DOI: 10.1046/j.1365-2125.1998.00758.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  40 in total

1.  Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies.

Authors:  J Loeper; V Descatoire; M Maurice; P Beaune; J Belghiti; D Houssin; F Ballet; G Feldmann; F P Guengerich; D Pessayre
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

2.  High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy.

Authors:  A Tran; J F Quaranta; S Benzaken; V Thiers; H T Chau; P Hastier; D Regnier; G Dreyfus; C Pradier; J L Sadoul
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

3.  Bioavailability of four pharmaceutical formulations of metronidazole tested on normal healthy volunteers.

Authors:  M N Muscará; G De Nucci
Journal:  Braz J Med Biol Res       Date:  1991       Impact factor: 2.590

4.  Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease.

Authors:  G Dusheiko; H Schmilovitz-Weiss; D Brown; F McOmish; P L Yap; S Sherlock; N McIntyre; P Simmonds
Journal:  Hepatology       Date:  1994-01       Impact factor: 17.425

5.  Liver/kidney microsome antibody type 1 and hepatitis C virus infection.

Authors:  F Lunel; N Abuaf; L Frangeul; P Grippon; M Perrin; Y Le Coz; D Valla; E Borotto; A M Yamamoto; J M Huraux
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

6.  Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.

Authors:  Z Abdel-Razzak; P Loyer; A Fautrel; J C Gautier; L Corcos; B Turlin; P Beaune; A Guillouzo
Journal:  Mol Pharmacol       Date:  1993-10       Impact factor: 4.436

7.  Persistent hepatitis C viraemia without liver disease.

Authors:  S Brillanti; M Foli; S Gaiani; C Masci; M Miglioli; L Barbara
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

8.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation.

Authors:  M L Shiffman; R A Fisher; A J Sanyal; L E Edinboro; V A Luketic; P P Purdum; P Raymond; M P Posner
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

10.  Anti-GOR and hepatitis C virus in autoimmune liver diseases.

Authors:  G Michel; A Ritter; G Gerken; K H Meyer zum Büschenfelde; R Decker; M P Manns
Journal:  Lancet       Date:  1992-02-01       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.